{"retracted":false,"update":{"timestamp":1476662400000,"doi":"10.1007/s10147-016-1052-3","type":"correction"},"doi":"10.1007/s10147-016-1039-0","journal":"International Journal of Clinical Oncology","publisher":"Springer Nature","title":"Erratum to: Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer"}
